Targeting the prognostic marker ALDH1 overcomes temozolomide resistance in human glioblastoma patients with unfavourable MGMT status

F. Ringel, A. Schäfer, J. Teufel, J. Gempt, Y.M. Ryang, H. Pape, B. Meyer & J. Schlegel
Objective: The prognosis of patients with glioblastoma (GBM) remains poor despite aggressive therapeutic regimens, including radical surgical resection, radiation and chemotherapy. Adjuvant chemotherapy with temozolomide (TMZ) significantly increased the overall survival but predominantely when the [for full text, please go to the a.m. URL]